19.2 Painless Vision Loss & Chronic Ophthalmic Disease
Key Takeaways
Macular degeneration, retinal detachment, diabetic retinopathy, amaurosis fugax, temporal arteritis and Roth spots are enumerated under retinal disease.
Central retinal artery occlusion is a stroke equivalent requiring urgent evaluation for a cardioembolic or carotid source.
Giant cell arteritis must be excluded in any patient over 50 with acute vision loss, and corticosteroids are started before biopsy.
Retinal detachment presents with flashes, floaters and a curtain-like field defect and requires urgent ophthalmology referral.
Annual dilated eye examination is recommended in diabetes because retinopathy is asymptomatic until advanced.
1. Painless Acute Vision Loss
Sudden, painless, monocular vision loss is a medical emergency requiring rapid diagnostic differentiation between arterial vascular occlusion, venous thrombosis, systemic inflammatory vasculitis, and mechanical retinal detachment.
| Condition | Pathophysiology & Etiology | Funduscopic Hallmarks | Key Diagnostic Workup | Emergency Management |
|---|---|---|---|---|
| Central Retinal Artery Occlusion (CRAO) | Embolic occlusion of central retinal artery (internal carotid artery atheroma, cardiogenic embolus, calcific valve plaque) | Diffusely pale, ischemic white/edematous retina with a distinct "Cherry-Red Spot" at the fovea; segmentation / "boxcarring" of retinal blood columns | Emergency Stroke Protocol: Carotid duplex ultrasound, Echocardiogram (TTE/TEE), Continuous ECG telemetry, MRI brain/DWI, ESR/CRP | Emergency stroke center admission; ocular massage, anterior chamber paracentesis (variable benefit); secondary stroke prevention (antiplatelet, statin, BP control) |
| Central Retinal Vein Occlusion (CRVO) | Thrombotic occlusion of central retinal vein at lamina cribrosa; associated with HTN, DM, hyperlipidemia, glaucoma, hypercoagulability | "Blood and thunder" fundus: Widespread flame-shaped and dot-blot hemorrhages across all 4 quadrants, engorged tortuous veins, disc edema, cotton-wool spots | Screen for vascular risk factors, thrombophilia panel (if young/unprovoked: Factor V Leiden, APS, protein C/S deficiency), serum protein electrophoresis | Ophthalmology referral; Intravitreal Anti-VEGF injections (Aflibercept, Ranibizumab) or Dexamethasone intravitreal implants for macular edema; PRP if neovascularization |
| Giant Cell Arteritis (GCA / A-AION) | Immune-mediated granulomatous vasculitis of posterior ciliary arteries supplying optic nerve head; age ≥50 years | Chalky-white, pale, edematous optic disc (Arteritic Anterior Ischemic Optic Neuropathy) with splinter hemorrhages; Relative Afferent Pupillary Defect (RAPD) | Markedly elevated ESR (often >50–100 mm/hr), elevated CRP, thrombocytosis; Temporal Artery Biopsy (≥2–3 cm specimen) | IMMEDIATE High-Dose Systemic Corticosteroids: IV Methylprednisolone 500–1000 mg/day for 3 days, then Oral Prednisone 1 mg/kg/day. DO NOT DELAY STEROIDS FOR BIOPSY (protects contralateral eye); Tocilizumab (anti-IL-6R) |
| Rhegmatogenous Retinal Detachment | Full-thickness retinal tear/hole allowing liquefied vitreous fluid to dissect into subretinal space, peeling neurosensory retina off RPE | Elevated, billowing, folded, gray-white detached retina; loss of normal red reflex; undulating with ocular movement; visible retinal tear/break | Dilated funduscopic exam with indirect ophthalmoscopy; B-scan ocular ultrasonography if media opacified by vitreous hemorrhage | Urgent vitreoretinal surgical intervention: Pneumatic retinopexy, Scleral buckle, or Pars plana vitrectomy; laser barrier photocoagulation for localized tears |
2. Chronic Ophthalmic Diseases for the Internist
Diabetic Retinopathy
Diabetic retinopathy is the leading cause of new blindness among working-age adults (aged 20–74 years) in developed nations.
- Pathophysiology: Chronic hyperglycemia triggers retinal capillary pericyte apoptosis, basement membrane thickening, microvascular leakage, capillary non-perfusion, and tissue ischemia, upregulating Vascular Endothelial Growth Factor (VEGF).
- Clinical Staging & Manifestations:
- Non-Proliferative Diabetic Retinopathy (NPDR):
- Mild/Moderate: Microaneurysms (earliest sign), small dot-and-blot intraretinal hemorrhages, hard lipid exudates (circinate rings), and cotton-wool spots (microinfarctions of the retinal nerve fiber layer).
- Severe NPDR (4-2-1 Rule): Intraretinal hemorrhages in all 4 quadrants, venous beading in ≥2 quadrants, or intraretinal microvascular abnormalities (IRMA) in ≥1 quadrant. High risk of rapid progression to proliferative disease.
- Proliferative Diabetic Retinopathy (PDR):
- Characterized by pathologic neovascularization originating from the optic disc (NVD) or retinal vessels elsewhere (NVE).
- Complications: Preretinal and vitreous hemorrhage (sudden painless vision loss with dark floating streaks), fibrovascular traction causing tractional retinal detachment, and neovascular glaucoma.
- Diabetic Macular Edema (DME): Fluid accumulation and retinal thickening involving the central macula/fovea; can occur at any stage of NPDR or PDR and is the leading cause of moderate visual impairment in diabetics.
- Non-Proliferative Diabetic Retinopathy (NPDR):
- Evidence-Based Management & Screening Guidelines:
- Systemic Optimization: Intensive glycemic control (target HbA1c <7.0%), strict blood pressure control (<130/80 mmHg), and lipid management substantially reduce retinopathy onset and progression (DCCT and UKPDS landmark trials).
- Intravitreal Anti-VEGF Therapy: First-line standard of care for center-involving diabetic macular edema and high-risk PDR (Aflibercept, Ranibizumab, or Faricimab).
- Panretinal Photocoagulation (PRP): Argon laser ablation of ischemic peripheral retina to decrease angiogenic VEGF drive and stabilize proliferative vessels.
- Screening Protocols:
- Type 2 Diabetes: Comprehensive dilated eye examination at the time of initial diagnosis, then annually.
- Type 1 Diabetes: Dilated eye examination within 5 years of diagnosis, then annually.
- Pregnancy in Pre-existing Diabetes: Dilated exam prior to conception or in first trimester, with close trimester monitoring.
Hypertensive Retinopathy
Retinal vascular changes reflect systemic end-organ microvascular damage from acute or chronic hypertension. Staged using the Keith-Wagener-Barker (KWB) Classification:
| KWB Grade | Key Funduscopic Findings | Pathophysiologic Mechanism | Clinical Significance |
|---|---|---|---|
| Grade 1 | Generalized and focal arteriolar narrowing; increased arteriolar light reflex ("copper wiring") | Diffuse arteriolar sclerosis and hypertonus | Chronic mild-to-moderate hypertension |
| Grade 2 | Grade 1 + Arteriovenous (AV) nicking / compression; "silver wiring" (opaque, whitish arteriolar wall) | Thickened sclerotic arteriole wall compresses underlying venule at crossing points | Longstanding sustained hypertension; marker of systemic atherosclerotic burden |
| Grade 3 | Grade 2 + Flame-shaped retinal hemorrhages, cotton-wool spots, hard exudates forming a "macular star" | Breakdown of blood-retinal barrier with focal retinal ischemia and lipid exudation | Moderate-to-severe hypertension; high correlation with stroke and nephrosclerosis |
| Grade 4 | Grade 3 + Papilledema (bilateral optic disc swelling with blurred margins, venous engorgement) | Severe intracranial and microvascular hypertension with axoplasmic flow stasis | Malignant / Hypertensive Emergency; mandates urgent inpatient BP reduction |
Age-Related Macular Degeneration (AMD)
Age-related macular degeneration is the leading cause of irreversible central visual loss in patients aged ≥65 years. Peripheral visual fields remain intact, but central visual acuity (reading, face recognition, driving) is severely impaired.
- Dry (Non-Exudative / Atrophic) AMD (85–90% of cases):
- Pathophysiology: Accumulation of acellular debris beneath the retinal pigment epithelium (RPE) forming focal extracellular yellow deposits known as drusen, progressing to geographic atrophy of the RPE and overlying photoreceptors.
- Symptoms: Gradual, progressive loss of central vision, difficulty reading in low light, and visual distortion (metamorphopsia, detected by wavy/distorted lines on an Amsler grid).
- Management: Smoking cessation is the most critical modifiable lifestyle intervention. Daily supplementation with the AREDS2 antioxidant formula (Vitamin C 500 mg, Vitamin E 400 IU, Zinc oxide 80 mg, Cupric oxide 2 mg, Lutein 10 mg, Zeaxanthin 2 mg — replaces beta-carotene to eliminate lung cancer risk in current/former smokers) reduces the 5-year risk of progression to advanced AMD by 25–30% in patients with intermediate drusen or unilateral advanced AMD. Novel complement C3/C5 inhibitors (Pegcetacoplan, Avacincaptad pegol) slow the rate of geographic atrophy expansion.
- Wet (Exudative / Neovascular) AMD (10–15% of cases, causes 90% of severe blindness):
- Pathophysiology: Pathologic growth of abnormal choroidal neovascular membranes (CNVM) extending through breaks in Bruch's membrane into the sub-RPE or subretinal space. These fragile vessels leak fluid and blood, leading to subretinal hemorrhage, lipid exudation, and eventual disciform fibrovascular scarring.
- Symptoms: Acute or subacute, rapid, painless distortion and severe drop in central vision with central dark blind spots (scotomas).
- First-Line Treatment: Immediate Intravitreal Anti-VEGF Injections (Aflibercept, Ranibizumab, Faricimab, or Bevacizumab) administered on a monthly or treat-and-extend regimen to halt vascular permeability, regress neovascularization, and preserve central vision.
A 72-year-old man with hypertension and coronary artery disease presents with a sudden, painless loss of vision in his right eye that occurred 45 minutes ago upon waking. Visual acuity is limited to counting fingers at 1 foot in the right eye and 20/20 in the left eye. Pupillary examination reveals a right relative afferent pupillary defect (RAPD). Dilated funduscopic examination reveals diffuse retinal pallor with ischemic whitening throughout the posterior pole and a prominent, well-demarcated cherry-red spot at the fovea. Segmented blood flow ('boxcarring') is visible in the retinal arterioles. Erythrocyte sedimentation rate (ESR) is 18 mm/hr and C-reactive protein is normal. What is the most appropriate next step in management?
Initiate high-dose intravenous Methylprednisolone 1000 mg daily for presumed giant cell arteritis
Activate an emergency stroke protocol and arrange urgent non-invasive vascular imaging including carotid duplex ultrasonography and echocardiography
Administer intravitreal Ranibizumab injections for central retinal vein thrombosis
Schedule elective outpatient laser panretinal photocoagulation within 4 weeks
Sections you finish are checked off in the contents.